Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Quarter to Quarter Aggressive Growth Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (458)	6/25/2000 9:01:00 PM
From: Ron Porter	Read Replies (1) \| Respond to of 6920

Your words herein "This is a positive and continues to validate CYTC's products. The test specified by Quest uses the sample taken from the ThinPrep vial. The CYTC ThinPrep will still be utilized as the initial test method. The Quest test would be added in extreme cases where doctors need an immediate follow on for high risk patients. The market has reacted negatively because they don't understand the technology (it isn't competitive, but rather complimentary) and this has created an excellent buying opportunity. Remember, we only have 20% of the US market and now have begun expansion to Europe. Bring on those Chinese women and the rest of Asia/Pacific. " would lead me to believe that this news article should have moved the stock up not down. I guess I go not completely understand. Since I believe that the Quest subsequent testing would come from "ThinPrep" from CYTC EXCLUSIVLY provided test. A plus not a minus for the validity of the CYTC system. Any comments would be appreciated. Ron